Surgical treatment experience for patients with stage I-III esophageal cancer
DOI:
https://doi.org/10.14739/2310-1210.2018.3.130822Keywords:
esophageal cancer, operative surgical procedures, lymph node excision, survivalAbstract
Today, esophageal cancer (EC) remains a complex oncological problem.
Aim of the work is to assess the survival rates of patients with the I–III stages esophageal cancer and esophagogastric junction.
Materials and methods. 50 patients with the I-III stages EC and esophagogastric junction cancer were operated in the Thoracic Surgery Department of Municipal Institution “Zaporizhzhia Regional Clinical Oncology Dispensary” for the period from 2010 to 2017. The Ivor–Lewis surgery was an operation of choice.
Results. While survival analysis it was noted that the 5-year overall survival rate among operated patients was 40.3 %, median survival made 21.0 months. In the patients with the I–II stages median survival time wasn't reached (more than 50.0 % of patients survived a 5-year follow-up period) and the 5-year overall survival rate made 50.9 % (P < 0.05), while in patients with the III stage median survival time made 13.0 months (P < 0.05).
Conclusions. The results of the surgical treatment of patients with EC and esophagogastric junction of the I–III stages in the Thoracic Surgery Department of Municipal Institution “Zaporizhzhia Regional Clinical Oncology Dispensary” did not differ from the overall results of this issue studies. At the same time acceptable indications of postoperative complications, mortality and overall survival have been reached.
References
Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W., Comber, H., et al. (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer, 49(6), 1374–1403. doi: 10.1016/j.ejca.2012.12.027.
Pickens, A., & Orringer, M. B. (2003) Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg, 76(4), S1367–1369. doi: https://doi.org/10.1016/S0003-4975(03)01202-5.
Fedorenko, Z. P., Mykhailovych, Yu. Y., Hulak, L. O., et al (2017) Rak v Ukrainí, 2015–2016 [Cancer in Ukraine, 2015–2016]. Biuleten Natsionalnoho kantser-reiestru Ukrainy, 18, 24–25. [in Ukrainian].
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) Global cancer statistics. CA Cancer J Clin, 61, 69–90. doi: 10.3322/caac.20107.
Castro, C., Bosetti, C., Malvezzi, M., Bertuccio, P., Levi, F., Negri, E., et al. (2014) Patterns and trends in esophageal cancer mortality and incidence in Europe (1980–2011) and predictions to 2015. Ann Oncol, 25, 283–290. doi: 10.1093/annonc/mdt486.
Ellis, F. H. J. (1999). Standard resection for cancer of the esophagus and cardia. Surg. Oncol. Clin. North. Am, 8, 279–294.
NCCN Guidelines Version 2.2017. Esophageal and Esophagogastric Junction Cancers, 39.
American Cancer Society (2008). American Cancer Society. Cancer Facts and Figures 2008. Atlanta.
Bumm, R., & Wong, J. (1994). More or less surgery for esophageal cancer: extent of lymphadenectomi in esophagectomy for squamous cells esophageal carcinoma: How mach in necessary. Dis. Esoph, 7, 151–155.
Collard, J.M. (1997). The stomach an esophageal substitute after total or subtotal esophagectomy. Univer Catholique de Louvan. Faculte de Medicine.
Rizk, N. P., Ishwaran, H., Rice, T. W., Chen, L. Q., Schipper, P. H., Kesler, K. A., et al. (2010) Optimum lymphadenectomy for esophageal cancer. Ann Surg, 251, 46–50. doi: 10.1097/SLA.0b013e3181b2f6ee.
Mariette, C., Dahan, L., Mornex, F., Maillard, E., Thomas, P.-A., Meunier, B., et al. (2014) Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol, 32, 2416–2422.
Markar, S. R., Gronnier, C., Pasquer, A., Duhamel, A., Beal, H., Théreaux, J., et al. (2016) Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study. Eur J Cancer, 56, 59–68. doi: 10.1016/j.ejca.2015.11.024.
Brusselaers, N., Mattsson, F., & Lagergren, J. (2014) Hospital and surgeon volume in relation to long-term survival after oesophagectomy: systematic review and meta-analysis. Gut, 63, 1393–1400. doi: 10.1136/gutjnl-2013-306074.
Stahl, M., Mariette, C., Haustermans, K., Cervantes, A., & Arnold, D. (2013) Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol., 6, vi51–6. doi: 10.1093/annonc/mdt342.
Sjoquist, K. M., Burmeister, B. H., Smithers, B. M., Zalcberg, J. R., Simes, R. J., Barbour, A., & Gebski, V. (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol, 12(7), 681–692. doi: 10.1016/S1470-2045(11)70142-5.
Markar, S., Gronnier, C., Duhamel, A., Pasquer, A., Théreaux, J., du Rieu, M. C., et al. (2015) Salvage surgery after chemoradiotherapyin the management of esophageal cancer: is it a viable therapeutic option? J Clin Oncol, 33(33), 3866–3873. doi: 10.1200/JCO.2014.59.9092.
Kranzfelder, M., Schuster, T., Geinitz, H., Friess, H., & Büchler, P. (2011) Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg, 98(6), 768–783. doi: 10.1002/bjs.7455.
Fokeev, S. D., Shojkhet, Ya. N., Lazarev, A. F., et al. (2006). Zavisimost' prodolzhitel'nosti zhizni bol'nykh pri rake pishchevoda ot vybora lecheniya [Dependence of life expectancy of patients with esophageal cancer from the choice of treatment]. Problemy klinicheskoj mediciny, 3, 50–53. [in Russian].
Khajruddinov, R. V. (2006). Sovremennye principy diagnostiki i khirurgicheskogo lecheniya raka pishhevoda [Modern principles of diagnosis and surgical treatment of cancer of the esophagus]. Vestnik khirurgii im. I.I. Grekova, 165(3), 48–51. [in Russian].
Davydov, M. I., Stilidi, I. S., Bokhyan, V. Yu., Suleimanov, E. A., Tryakin, A. A., Kononets, P. V., & Tyulyandin, S. A. (2005). Promezhutochnye rezul'taty primeneniya predoperacionnoj khimioterapii i rasshirennoj subtotal'noj rezekcii pishhevoda pri rake [Intermediate results of the use of preoperative chemotherapy and extended subtotal resection of the esophagus in cancer]. Annaly khirurgii, 3, 27–32. [in Russian].
Davydov, M. I., Stilidi, I. S., Ter-Ovanesov, M. D., & Polockij, B. E. (2006). Rak pishhevoda: sovremennye podhody k diagnostike i lecheniyu [Esophageal cancer: modern approaches to diagnosis and treatment]. Russkij medicinskij zhurnal, 14, 1006–1015. [in Russian].
Chissov, V. I., & Dar'yalova, S. L. (2007). Onkologija [Oncology]. Moscow : [in Russian].
Mamontov, A. C. (2003). Kombinirovannoe lechenie raka pishhevoda [Combined treatment of esophageal cancer]. Fakticheskaya onkologiya, 4, 2(14), 76–82. [in Russian].
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
